

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: <http://www.elsevier.com/locate/crvasa>

Guidelines

Summary of 2013 ESH/ESC Guidelines for the management of arterial hypertension

Prepared by the Czech Society of Hypertension/ Czech Society of Cardiology[☆]



Jan Filipovský^{a,*}, Jiří Widimský Jr.^b, Jindřich Špinar^c

^a Department of Internal Medicine II, Charles University, Medical Faculty and Faculty Hospital, Pilsen, Czech Republic

^b Department of Internal Medicine III, Charles University, 1st Medical Faculty and General Faculty Hospital, Prague, Czech Republic

^c Department of Cardiology, Masaryk University, Medical Faculty and Faculty Hospital, Brno, Czech Republic

Authors of the original ESH/ESC update document [1]: Giuseppe Mancia, Robert Fagard on behalf of the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

ARTICLE INFO

Article history:

Received 4 July 2014

Accepted 31 July 2014

Available online 6 October 2014

Keywords:

Guidelines

Arterial hypertension

Diagnose

Treatment



ČESKÁ KARDIOLOGICKÁ SPOLEČNOST
THE CZECH SOCIETY OF CARDIOLOGY

[☆] For permissions: please e-mail: guidelines@escardio.org.

* Corresponding author at: Department of Medicine II, Medical School in Pilsen, University Hospital in Pilsen, E. Beneše 13, 305 99 Plzeň, Czech Republic. Tel.: +420 377 402 439; fax: +420 377 402 374.

E-mail address: filipovsky@fnplzen.cz (J. Filipovský).

Abbreviations: ABPM, ambulatory blood pressure monitoring; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BP, blood pressure; CHD, coronary heart disease; CKD, chronic kidney disease; CV, cardiovascular; DBP, diastolic blood pressure; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ESH/ESC, European Society of Hypertension/European Society of Cardiology; ESRD, end-stage renal disease; HBPM, home blood pressure monitoring; ISH, isolated systolic hypertension; LV, left ventricle; LVH, left ventricular hypertrophy; OD, organ damage; PAD, peripheral arterial disease; PWV, pulse wave velocity; RAS, renin-angiotensin system; RCT, randomized controlled trial; SBP, systolic blood pressure; WCH, white-coat hypertension.

<http://dx.doi.org/10.1016/j.crvasa.2014.07.007>

0010-8650/© 2014 European Society of Cardiology. All rights reserved. Published by Elsevier Urban & Partner Sp.z.o.o. on behalf of The Czech Society of Cardiology. Open access under [CC BY-NC-ND license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Epidemiological aspects	e496
1.1. Definition and classification of hypertension	e496
1.2. Hypertension and total cardiovascular risk	e497
2. Diagnostic evaluation	e498
2.1. Blood pressure measurement	e498
2.1.1. Office blood pressure	e498
2.1.2. Out-of-office BP	e498
2.1.3. White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension	e499
2.1.4. Central blood pressure	e501
2.2. Medical history	e501
2.3. Physical examination	e501
2.4. Laboratory investigations	e501
2.5. Asymptomatic organ damage	e501
2.5.1. Heart	e501
2.5.2. Blood vessels	e501
2.5.3. Kidney	e501
2.5.4. Fundoscopy	e501
2.5.5. Brain	e502
2.6. Searching for secondary forms of hypertension	e503
3. Treatment approach	e503
3.1. When to initiate antihypertensive drug treatment	e503
3.1.1. Grade 2 and 3 hypertension and high-risk grade 1 hypertension	e503
3.1.2. Low-to-moderate risk, grade 1 hypertension	e503
3.1.3. High normal blood pressure	e505
3.2. Blood pressure treatment targets	e505
3.2.1. Recommendations of previous guidelines	e505
3.2.2. Hypertension in the elderly	e505
3.2.3. Diabetes mellitus	e505
3.2.4. Previous cardiovascular events	e505
3.2.5. Renal disease	e507
3.2.6. Clinic vs. home and ambulatory blood pressure targets	e507
4. Treatment strategies	e508
4.1. Lifestyle changes	e508
4.2. Pharmacological therapy	e508
4.2.1. Choice of antihypertensive drugs	e508
4.2.2. Monotherapy and combination therapy	e508
5. Treatment strategies in special conditions	e510
5.1. White-coat hypertension	e510
5.2. Masked hypertension	e510
5.3. Elderly	e510
5.4. Young adults	e511
5.5. Women	e511
5.6. Diabetes mellitus	e512
5.7. Metabolic syndrome	e512
5.8. Obstructive sleep apnoea	e512
5.9. Diabetic and non-diabetic nephropathy	e513
5.10. Cerebrovascular disease	e514
5.11. Heart disease	e515
5.11.1. Coronary heart disease	e515
5.11.2. Heart failure	e515
5.11.3. Atrial fibrillation	e515
5.11.4. Left ventricular hypertrophy	e515
5.12. Atherosclerosis, arteriosclerosis, and peripheral artery disease	e516
5.13. Sexual dysfunction	e516
5.14. Resistant hypertension	e516
5.15. Hypertensive emergencies	e517
5.16. Perioperative management of hypertension	e517

Download English Version:

<https://daneshyari.com/en/article/5877433>

Download Persian Version:

<https://daneshyari.com/article/5877433>

[Daneshyari.com](https://daneshyari.com)